0
个在招岗位
- 公司介绍
简介
德国美天旎生物技术有限公司成立于1989年，现在已经发展成为拥有1100名雇员，在18个国家有分支机构的跨国生物技术企业。
公司致力于开发，制造和销售超过1000种产品和服务，尤其在细胞生物学，免疫学，再生医学和分子生物学等领域享有较高的声誉。 美天旎生物技术公司开发的MACS技术，已经成为磁性细胞分选领域的金标准。
联合纳米级的MACS微珠和专利的MACS分选柱以及MACS分选器，MACS技术提供了一种多样化的应用技术：从小规模到大规模分选，从细胞到生物分子的分离，从实验室到临床前研究，直至利用cliniMACS系统分选出成体干细胞。
现在美天旎隆重地推出了一款新型的流式细胞仪—MACSQuant流式细胞仪，能够高敏感性的进行多色流式分析，能够进行自动化的细胞分析，配合有强大的，创新性的特征，将科研研究引领到一个新的阶段。
公司的分子生物学业务部门开发销售分子生物学相关产品，提供生物信息学和基因表达谱服务以及生产转基因疾病模型。 公司内部的R&D部门持续开发新的试剂和仪器，用于免疫学，细胞和分子生物学，生物信息学和干细胞技术-用研究者的专业来服务于研究者。
The Story
Since pioneering MACS magnetic cell separation technology in 1990, we have grown into a vibrant, multinational team of more than 1200 biomedical scientists, physicians, engineers, and support groups. We develop and manufacture a portfolio of outstanding products ranging from unique cell labeling reagents, through sophisticated cell separation and analysis devices, to innovative systems for clinical applications.
The Passion
Our commitment is to the advancement of biomedical research and cellular therapy. Our passion is the development of technologies that impact on basic research and clinical applications. Our customers value our reputation and years of experience in providing products that make a difference.
The Portfolio
The MACS Solutions portfolio of outstanding tools for the translation from basic research to therapy, addresses techniques of sample preparation, cell separation and analysis, molecular analysis, cell culture, therapeutic plasma apheresis. From research tools to GMP reagents for sophisticated applications, such as cellular therapy, the creativity of our interdisciplinary teams is reflected in the excellence of our products.
The Promise
"Researchers working for researchers" is the concept that enables us to fulfill our promise to provide pioneering products to our customers. By integrating research, development and manufacturing processes, we have a unique understanding of all procedures involved in the provision of high quality products. Customers can rely on our expertise and on our support.